Combination therapy for extensively-drug resistant gram-negative bacteria

References

• Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15:1351–1370.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–796.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Antimicrobial resistance: no action today, no cure tomorrow. Geneva, Switzerland: WHO Press; 2011. Available from http://www.who.int/world-health-day/2011/en/index.html
   Google Scholar
• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20:862–872.
   PubMed Web of Science ®Google Scholar
• Kmeid JG1, Youssef MM, Kanafani ZA, et al. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther. 2013;11:1355–1362.
   PubMed Web of Science ®Google Scholar
• Kalil AC. Antibiotic combination therapy for patients with gram-negative septic shock. Crit Care Med. 2017. [Epub ahead of print]. DOI:10.1097/CCM.0000000000002677
   Google Scholar
• Miriagou V, Cornaglia G, Edelstein M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16:112–122.
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–458.
   PubMed Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:29–39.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Maraolo AE, Viscoli C. Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies. Eur J Clin Microbiol Infect Dis. 2017;36:1707–1709.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873–5884.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Souli M, Galani I, et al. Colistin: still a lifesaver for the 21st century? Expert Opin Drug Metab Toxicol. 2017;13:59–71.
   PubMed Web of Science ®Google Scholar
• Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57:5104–5111.
   PubMed Web of Science ®Google Scholar
• Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37:244–247.
   PubMed Web of Science ®Google Scholar
• Tängdén T, Hickman RA, Forsberg P, et al. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother. 2014;58:1757–1762.
   PubMed Web of Science ®Google Scholar
• Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:3002–3004.
   PubMed Web of Science ®Google Scholar
• Yu W, Zhou K, Guo L, et al. In vitro pharmacokinetics/pharmacodynamics evaluation of fosfomycin combined with amikacin or colistin against KPC2-producing Klebsiella pneumoniae. Front Cell Infect Microbiol. 2017 16;7:246.
   PubMed Web of Science ®Google Scholar
• Diep JK, Jacobs DM, Sharma R, et al. Polymyxin B in combination with rifampin and meropenem against polymyxin b-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017 24;61(pii):e02121–16.
   PubMedGoogle Scholar
• Zhao M, Bulman ZP, Lenhard JR, et al. Pharmacodynamics of colistin and fosfomycin: a ‘treasure trove’ combination combats KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017;72:1985–1990. [Epub ahead of print]. DOI:10.1093/jac/dkx070
   PubMed Web of Science ®Google Scholar
• Albur MS, Noel A, Bowker K, et al. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int J Antimicrob Agents. 2015;46:560–567.
   PubMed Web of Science ®Google Scholar
• Toledo PVM, Junior AAA, Arend LN, et al. Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay. Antimicrob Agents Chemother. 2015;59:4301–4304.
   PubMed Web of Science ®Google Scholar
• Betts JW, Phee LM, Hornsey M, et al. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58:3541–3546.
   PubMed Web of Science ®Google Scholar
• Michail G, Labrou M, Pitiriga V, et al. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2013;57:6028–6033.
   PubMed Web of Science ®Google Scholar
• Demiraslan H, Dinc G, Ahmed SS, et al. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination. J Chemotherapy. 2014;26:271–281.
   Web of Science ®Google Scholar
• Mouloudi E, Protonotariou E, Zagorianou A, et al. Bloodstream infections caused by metallo-b-lactamase Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010;31:1250–1256.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798–1803.
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents. 2012;56:2108–2113.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–950.
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19:E23–30.
   PubMed Web of Science ®Google Scholar
• Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multicentre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20:O117–O123.
   PubMed Web of Science ®Google Scholar
• De Oliveira MS, De Assis DB, Freire MP, et al. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect. 2015;21:179.e1–7.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–2143.
   PubMed Web of Science ®Google Scholar
• Gomez-Simmonds A, Nelson B, Eiras DP, et al. Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2016;60:3601–3607.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91:1076–1081.
   PubMed Web of Science ®Google Scholar
• Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47:335–339.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22:444–450.
   PubMed Web of Science ®Google Scholar
• Papadimitriou-Olivgeris M, Fligou F, Bartzavali C, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality. Eur J Clin Microbiol Infect Dis. 2017;36:1125–1131.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother. 2017 61;pii:e02349–16.
   Google Scholar
• Alexander E, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: 1.55 results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis. 2017;4:ofx063.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, De Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726–734.
   PubMed Web of Science ®Google Scholar
• Machuca I, Gutiérrez-Gutiérrez B, Gracia-Ahufinger I, et al. Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance: importance of combination therapy without colistin and carbapenems. Antimicrob Agents Chemother. 2017 61;pii:e00406–17.
   Google Scholar
• Cristina ML, Alicino C, Sartini M, et al. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area. J Infect Public Health. 2017;pii:S1876–0341(17)30146.
   Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, De Cueto M, et al. A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae. Mayo Clin Proc. 2016;91:1362–1371.
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, Giacobbe DR, et al. Effect of combination therapy containing a high dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2017;pii:S0924-8579(17)30311–4.
   Google Scholar
• Del Bono V, Giacobbe DR, Marchese A, et al. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence. 2017;8:66–73.
   PubMed Web of Science ®Google Scholar
• Pea F, Della Siega P, Cojutti P, et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents. 2017;49:255–258.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae Infections. Clin Microbiol Infect. 2017;pii:S1198-743X(17)30499–8. [Epub ahead of print]. DOI:10.1016/j.cmi.2017.08.030
   Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam is superior to other treatment regimens against Carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017 61;pii:e00883–17.
   Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618.
   PubMed Web of Science ®Google Scholar
• Poirel L, Kieffer N, Nordmann P. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71:156–161.
   PubMed Web of Science ®Google Scholar
• Oliva A, Scorzolini L, Cipolla A, et al. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value. J Antimicrob Chemother. 2017;72:1981–1984.
   PubMed Web of Science ®Google Scholar
• Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2013;41:582–585.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Galani L, Baziaka F, et al. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57:2388–2390.
   PubMed Web of Science ®Google Scholar
• Souli M, Karaiskos I, Masgala A, et al. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2017;36:1305–1315.
   PubMed Web of Science ®Google Scholar
• Venugopalan V, Nogid B, Le TN, et al. Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice. Infect Dis (Lond). 2017;49:v867–870.
   PubMed Web of Science ®Google Scholar
• De Pascale G, Martucci G, Montini L, et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study. Crit Care. 2017;21:173.
   PubMed Web of Science ®Google Scholar
• Oliva A, Scorzolini L, Castaldi D, et al. Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Infect. 2017;74(1):103–106.
   PubMed Web of Science ®Google Scholar
• Bonnin RA, Nordmann P, Poirel L. Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert Rev Anti Infect Ther. 2013;11:571–583.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents. 2008;32:106–119.
   PubMed Web of Science ®Google Scholar
• Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8–18.
   PubMed Web of Science ®Google Scholar
• Soudeiha MAH, Dahdouh EA, Azar E, et al. In vitro evaluation of the colistin-carbapenem combination in clinical isolates of A. baumannii using the checkerboard, Etest, and time-kill curve techniques. Front Cell Infect Microbiol. 2017;7:209–223.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Falci DR. Polymyxins combined with other antibiotics for the treatment of multi-resistant gram negative bacteria. Ppcr. 2015;1:91–96.
   Google Scholar
• Mohammadi M, Khayat H, Sayehmiri K, et al. Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis. Open Microbiol J. 2017;11:63–71.
   PubMedGoogle Scholar
• Cai X, Yang Z, Dai J, et al. Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamics model. Int J Antimicrob Agents. 2017;49:609–616.
   PubMed Web of Science ®Google Scholar
• Galani I, Orlandou K, Moraitou H, et al. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2014;43:370–374.
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 2004;54:1085–1091.
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Lee J, et al. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents. 2009;33:33–39.
   PubMed Web of Science ®Google Scholar
• Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:1165–1172.
   PubMed Web of Science ®Google Scholar
• Yang YS, Lee Y, Tseng KC, et al. In vivo and In vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:4047–4054.
   PubMed Web of Science ®Google Scholar
• Mutlu Yilmaz E, Sunbul M, Aksoy A, et al. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;40:332–336.
   PubMed Web of Science ®Google Scholar
• Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents. 2007;29:51–55.
   PubMed Web of Science ®Google Scholar
• Fan B, Guan J, Wang X, et al. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, difampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model. PLoS One. 2016;17(11):e0157757.
   Google Scholar
• Cirioni O, Simonetti O, Pierpaoli E, et al. Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis. Diagn Microbiol Infect Dis. 2016;86:392.
   PubMed Web of Science ®Google Scholar
• Yang H, Lv N, Hu L, et al. In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model. Infect Dis (Lond). 2016;48:189–194.
   PubMed Web of Science ®Google Scholar
• Lim SK, Lee SO, Choi SH, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci. 2011;26:325–331.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;58:851–858.
   PubMed Web of Science ®Google Scholar
• Kim WY, Moon JY, Huh JW, et al. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS One. 2016;11:e0150642.
   PubMed Web of Science ®Google Scholar
• López-Cortés LE, Cisneros JM, Fernández-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother. 2014;69:3119–3126.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy. 2013;59:225–231.
   PubMed Web of Science ®Google Scholar
• Kalin G, Alp E, Akin A, et al. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection. 2014;42:37–42.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349–358.
   PubMed Web of Science ®Google Scholar
• Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014;33:1311–1322.
   PubMed Web of Science ®Google Scholar
• Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141:1214–1222.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58:5598–5601.
   PubMed Web of Science ®Google Scholar
• Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control. 2012;40:983–987.
   PubMed Web of Science ®Google Scholar
• Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9:476–485.
   PubMed Web of Science ®Google Scholar
• Simsek F, Gedik H, Yildirmak MT, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol. 2012;30:448–452.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194–199.
   PubMed Web of Science ®Google Scholar
• Tsioutis C, Kritsotakis EI, Karageorgos SA, et al. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents. 2016;48:492–497.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Vieira FJ, Antochevis LC, et al. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2015;59:6575–6580.
   PubMed Web of Science ®Google Scholar
• Freire MP, De Oliveira Garcia D, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22:352–358.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015;41:2057–2075.
   PubMed Web of Science ®Google Scholar
• Peña C, Suarez C, Gozalo M, et al. For the Spanish Network for research in Infectious Diseases (REIPI). Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother. 2012;56:1256–1272.
   Web of Science ®Google Scholar
• Nelson RE, Slayton RB, Stevens VW, et al. Attributable mortality of healthcare-associated infections due to multidrug-resistant gram-negative bacteria and methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2017;1:1–9.
   Google Scholar
• Safdar N, Handlesman J, Makie DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis. 2004;4:519–527.
   PubMed Web of Science ®Google Scholar
• Lora-Tamayo J, Murillo O, Bergen PJ, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother. 2014;69:2434–2442.
   PubMed Web of Science ®Google Scholar
• Di X, Wang R, Liu B, et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem resistant Pseudomas aeruginosa. The J Antibiotics. 2015;68:551–555.
   Web of Science ®Google Scholar
• Safarika A, Galani I, Pistiki A, et al. Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis. 2015;34:317–323.
   PubMed Web of Science ®Google Scholar
• Tängdén T, Karvanen M, Friberg LE, et al. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. Infect Dis. 2017;49:521–527.
   Web of Science ®Google Scholar
• Aoki N, Tateda K, Kikuchi K, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63:534–542.
   PubMed Web of Science ®Google Scholar
• Cirioni O, Ghiselli R, Orlando F, et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit Care Med. 2007;35:1717–1723.
   PubMed Web of Science ®Google Scholar
• Cirioni O, Ghiselli R, Silvestri C, et al. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa Strain. Antimicrob Agents Chemother. 2007;51:2005–2010.
   PubMed Web of Science ®Google Scholar
• Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37:e154–60.
   PubMed Web of Science ®Google Scholar
• Furtado G, d’Azevedo P, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Intern J Antimicrob Agents. 2007;30:315–319.
   PubMed Web of Science ®Google Scholar
• Samonis G, Vardakas KZ, Kofteridis DP, et al. Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections. Infection. 2014;42:721–728.
   PubMed Web of Science ®Google Scholar
• Peña C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis. 2013;57:208–216.
   PubMed Web of Science ®Google Scholar
• Ribera A, Benavent E, Lora-Tamayo J, et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus b-lactams. J Antimicrob Chemother. 2015;70:3357–3365.
   PubMed Web of Science ®Google Scholar